



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : A.K. Gunnar Aberg  
Serial No. : 10/677,527  
Filed : October 2, 2003  
For : METHODS FOR TREATING URINARY INCONTINENCE AND  
OTHER DISORDERS USING TROSPIMUM  
Examiner : Not yet assigned  
Art Unit : Not yet assigned  
Attorney  
Docket No. : 559P021


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Sir:

INFORMATION DISCLOSURE STATEMENT


The Examiner is respectfully requested to consider the documents which are listed on the attached form PTO 1449.

Copies of the documents listed on the attached form are filed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 30, 2003

  
Signature: Kevin S. Lemack  
Date: December 30, 2003

Respectfully submitted,

  
Kevin S. Lemack  
Attorney for Applicants  
Registration No. 32,579  
Niels & Lemack  
176 E. Main Street  
Westboro, MA 01581  
TEL: (508) 898-1818



<b>FORM PTO-1449</b> <b>LIST OF PATENTS AND PUBLICATIONS FOR</b> <b>APPLICANT'S INFORMATION DISCLOSURE</b> <b>STATEMENT</b>	<b>ATTY. DOCKET NO.</b> 559P021	<b>SERIAL NO.</b> 10/677,527
	A.K. Gunnar Aberg	
	<b>FILING DATE</b> October 2, 2003	<b>GROUP</b> Not yet assigned

### REFERENCE DESIGNATION

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3,480,626	11/1969	Pfleger et al.	260	247.2	
	AB	5,998,430	12/1999	Schwantes et al.	514	299	
	AC	6,482,837	11/2002	Wood	514	315	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA							
	BB							
	BB							

### OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Pharmacology & Toxicology 1999, 85, 299-304; Svane Beckmann-Knopp et al.; "Inhibitory Effects of Trosipium Chloride on Cytochrome P450 Enzymes in Human Liver Microsomes"
	CB	Bertholdt H. et al., Arzneimittel-Forsch, 17; 719-726.
	CC	Biochemical Pharmacology, Vol. 22, pp. 3099-3108. Pergamon Press, 1973; Yung-Chi Cheng et al.; "Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which causes 50 per cent Inhibition (I50) of an Enzymatic Reaction"
	CD	The Lancet; vol. 338; August 10, 1991 pp. 344-345; M.J. Connolly et al.; "Torsades de pointes ventricular tachycardia and terodiline"
	CE	Chrysalis; "P.a. Gayheart-Walsten, et al.; "Effects of a New Non-Sedating Antihistamine on QTc Interval in a Newly Developed Guinea Pig Model"
	CF	Journal of Cardiovascular Pharmacology; 37: 607-618; 2001; Gary A. Gintant et al.; "The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis"
	CG	Dig Dis 1992; 10: 38-45; Juha M. Gronroos et al.; "Cholinergic Hypothesis of Alcoholic Pancreatitis"
	CH	Clinical Pharmacology & Therapeutics July 1996 ; 07019901; pp. 89-98; Kenneth Hartigan-Go, MD et al.; "Stereoselective Cardiotoxic Effects of Terodiline"
	CI	Abstracts 487-488; 85A; Hofner et al.; "Tolerability and Efficacy of Trosipium Chloride in a Long-Term Treatment (52 weeks) in Patients with Urge-Syndrome: A Double-Blind, Controlled, Multicentre Clinical Trial"
	CJ	Ital Heart J. Suppl. 2000; 1 (3): 419-422; Imperadore et al.; "Arresto cardiaco da fibrillazione ventricolare in corso di pancreatite acuta biliare: descrizione di un caso clinico e ipotesi eziopatogenetiche"
	CK	Page from Medscape from WEBMD; Rhythm disorders in gallstones;

	CL		British Journal of Pharmacology (2000) 131, 245-254; Stephen E. Jones et al.; "Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K <sup>+</sup> currents and action potentials"
	CM		The Journal of Pharmacology and Experimental Therapeutics; vol. 247, No. 3; pp. 867-872; James F. Kachur et al.; "R and S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder and Intestine"
	CN		Pharmacology & Toxicology 1998, 82, 161-166; Eeva Lukkari et al.; "Cytochrome P450 Specificity of Metabolism and Interactions of Oxybutynin in Human Liver Microsomes"
	CO		British Journal of Urology (1995), 75, 452-456; H. Madersbacher et al.; "Tropium Chloride Versus Oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia"
	CP		The Journal of Urology; Vol. 148, 595-597, August 1992; Charlotte A. Massad et al.; "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride"
	CQ		The Journal of Pharmacology and Experimental Therapeutics; Vol. 256, No. 2; L.Noronha-Blob et al.; "Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization at M1, M2 and M3 Muscarinic Receptors and in Vivo Effects on Urinary Bladder Contraction, Mydriasis and Salivary Secretion in Guinea Pigs"
	CR		Bur J Clin Pharmacol (1994) 47: 337-343; A. Pietzko et al.; "Influences of tropium chloride and oxybutynin on quantitative EEG in healthy volunteers"
	CS		Drug Metabolism and Disposition Vol. 26, No. 4 pp. 289-293; Hans Postlind et al.; "Tolterodine, A New Muscarinic Receptor Antagonist, Is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes"
	CT		The Journal of Pharmacology and Experimental Therapeutics; Vol. 290, No. 3; pp. 1417-1426; Shuba et al.; "Action Potentials, Contraction, and Membrane Currents in Guinea Pigs Ventricular Preparations Treated with the Antispasmodic Agent Terodiline"
	CU		Arzneimittel-Forschung/Drug Research 48 (11), 10, 1012-1018 (1998); Smith et al. "Comparison of the Antimuscarinic and Antispasmodic Actions of Racemic Oxybutynin and Desethyloxbutynin and Their Enantiomers with Those of Racemic Terodiline"
	CV		Page from Medscape from WEB MD; "Effects of Tolterodine, Tropium Chloride, and oxybutynin on the central nervous system"
	CW		Clin Drug Invest 23(6); 395-404, 2003; Diefenbach et al.; "Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Tropium Chloride and Placebo on Sleep in Healthy Young Volunteers".
EXA MINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <i>and</i> not considered. Include copy of this form with next communication to applicant.			



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)  
Approved for use through 10/31/2002, OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/677,527
Filing Date	October 2, 2003
First Named Inventor	A.K. Gunnar Aberg
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	559P021

Total Number of Pages in This Submission

## ENCLOSURES (check all that apply)

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment / Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)<br><input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br>-Form PTO-1449<br>-References cited - 26 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Kevin S. Lemack  
Niels & Lemack

Signature

Date

December 30, 2003

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Dec. 30, 2003

Typed or printed name

Kevin S. Lemack

Signature

Date December 30, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.